Latham & Watkins advised Topgolf Callaway on the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo advised Invited, Inc. Topgolf Callaway Brands Corp. (NYSE: MODG)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Gossamer Bio in the transaction. Gossamer Bio, Inc. (Nasdaq: GOSS) announced that it has entered into a securities purchase agreement with institutional...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises eFFECTOR Therapeutics in US$7.5 million registered direct offering. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Icosavax on the offering. Icosavax, Inc. (Nasdaq: ICVX) has announced that it has entered into a securities purchase agreement with investors in a...
You must be a Standard 1 Year member to access this content.
Cooley advised Longboard Pharmaceuticals on the offering, and Latham & Watkins advised the underwriters involved. Longboard Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Gossamer Bio in the transaction. Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Bionomics in the offering. Bionomics Limited, a clinical-stage biopharmaceutical company, has announced the pricing of its initial public offering in the United States...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
